SYNLOGIC, INC. Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount
SYNLOGIC, INC. (SYBX) reported Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount of $153.00 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-12.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets
us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount · last filed 2026-03-12
- SYNLOGIC, INC. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2025 was $153.00K.
- SYNLOGIC, INC. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2024 was -$9.38M.
- SYNLOGIC, INC. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2023 was -$15.46M.
- SYNLOGIC, INC. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2022 was -$19.12M.
| Period end | Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount 12 month | Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount 12 month as first filed |
|---|---|---|
| 2025-12-31 | $153.00K 10-K · filed 2026-03-12 | |
| 2024-12-31 | -$9.38M 10-K · filed 2026-03-12 | |
| 2023-12-31 | -$15.46M 10-K · filed 2025-03-06 | |
| 2022-12-31 | -$19.12M 10-K · filed 2024-03-19 | |
| 2021-12-31 | -$17.69M 10-K · filed 2023-03-29 | |
| 2020-12-31 | -$18.96M 10-K · filed 2022-03-17 | $18.96M 10-K · filed 2021-03-25 |
| 2019-12-31 | $13.54M 10-K · filed 2021-03-25 | |
| 2018-12-31 | $13.78M 10-K · filed 2020-03-12 | |
| 2017-12-31 | $13.46M 10-K · filed 2019-03-12 | |
| 2016-12-31 | $8.70M 10-K · filed 2018-03-20 | $9.30M 10-K · filed 2017-03-15 |
| 2015-12-31 | $9.00M 10-K · filed 2016-03-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |